Cures Within Reach’s mission is to leverage the speed, safety and cost-effectiveness of repurposing, testing already approved therapies for unsolved diseases: driving more treatments to more patients more quickly.
Cures Within Reach is the philanthropic leader in drug, device and nutraceutical repurposing research, which has the potential to transform the lives of patients with unsolved diseases by delivering treatments that can be used in the near-term. Our focus: we find and fund proof-of-concept clinical trials that, once successful, de-risk and catalyze follow-on funding, building the clinical evidence required for regulatory approval or to support off-label use by patients everywhere.
Upcoming Events
Virtual Event: Initiating Outreach for Engaging Community-Based Organizations in Clinical Trials
October 27, 2026 at 5pm ET: While the value of engaging community health, social services and faith-based organizations to support clinical trials is tangible, many clinical research teams don’t know where and how to begin. This event will discuss best practices when building relationships with community-based organizations (CBOs), trusted by patients who often do not know of or participate in clinical trials. Free registration through Oct 20.
Check out our 2025 Annual Report available here!
Read about our 20th anniversary celebration and our record-breaking 2025:
- $17 million raised in catalytic, follow-on funding for our funded research
- A record 16 clinical trials started
- A record 12 clinical trials completed
- A record 16 clinical trials selected, already underway or starting soon
- A record number of submissions received
Learn about some of our 2026 initiatives:
in Pediatrics
for Veterans/Military
and in AI Validation
Our AI Validation RFPs
The first ever RFP to fund clinical trials that will validate AI-driven drug-disease matches was open in 2025, resulting in 6 validation trials selected, starting soon. Read more details here.
Our 2026 AI Validation RFP deadline has passed and submissions are under review. These investigator-initiated, proof of concept, Phase I or Phase IIA clinical repurposing trials will include AI-generated data as part of the preclinical support for the trial. Eligibility: any unsolved disease is eligible; both on- and off-patent drugs and biologics are eligible, although there is a preference for off-patent; and data from any AI model is eligible, although there is a preference for openly accessible models and for models developed by nonprofits/government. Visit our Funding Opportunity RFP page for details!
Diseases Researched
Repurposing Trials Funded
Institutions Funded
Success Stories
Millions of Dollars in Clinical Trial Funding
